Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRD007 in children with DMD or BMD
NCT01540604Phase 2Completed
- Sponsor
- RSPR Pharma
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemirolast in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), sponsored by RSPR Pharma. Primary endpoints: Safety and Tolerability at 12 weeks and Clinical Efficacy at 12 weeks. Status: completed.
02
Drugs
pemirolast
03
Conditions
Duchenne muscular dystrophy (DMD)Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT01540604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01540604.